Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free IMUX Stock Alerts

Immunic (IMUX) Financials

Immunic logo
$11.28 +0.66 (+6.21%)
Closing price 04:00 PM Eastern
Extended Trading
$10.86 -0.41 (-3.68%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Immunic

Annual Income Statements for Immunic

This table shows Immunic's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -52 -41 -52 -12 -35 -44 -93 -120 -94 -101 -97
Consolidated Net Income / (Loss)		 -52 -41 -52 -12 -35 -44 -93 -120 -94 -101 -97
Net Income / (Loss) Continuing Operations		 -52 -41 -52 -12 -35 -44 -93 -120 -94 -101 -97
Total Pre-Tax Income 		-52 -41 -52 -12 -35 -44 -93 -120 -94 -101 -97
Total Operating Income		 -52 -41 -53 -12 -37 -49 -92 -119 -99 -98 -103
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 52 41 53 12 37 49 92 119 99 98 103
Selling, General & Admin Expense		 12 11 13 2.40 15 10 13 15 16 18 21
Research & Development Expense		 40 30 39 9.60 23 39 61 71 83 80 82
Total Other Income / (Expense), net		 0.10 0.30 0.58 0.46 2.10 4.95 -1.28 -0.92 5.61 -2.46 6.06
Interest & Investment Income		 0.06 0.28 0.65 -0.00 0.11 0.06 0.07 1.04 3.08 3.39 1.04
Other Income / (Expense), net		 0.04 0.01 -0.07 0.46 1.99 4.90 -1.35 -1.96 2.54 -5.85 5.02
Basic Earnings per Share		 ($2.07) ($1.31) ($1.31) ($13.63) ($4.52) ($2.81) ($3.93) ($3.78) ($2.11) ($1.00) ($0.62)
Weighted Average Basic Shares Outstanding		 25.15M 31.39M 39.86M 846.95K 7.72M 15.66M 23.65M 31.82M 44.32M 100.17M 155.69M
Diluted Earnings per Share		 ($2.07) ($1.31) ($1.31) ($13.63) ($4.52) ($2.81) ($3.93) ($3.78) ($2.11) ($1.00) ($0.62)
Weighted Average Diluted Shares Outstanding		 25.15M 31.39M 39.86M 846.95K 7.72M 15.66M 23.65M 31.82M 44.32M 100.17M 155.69M
Weighted Average Basic & Diluted Shares Outstanding		 25.15M 31.39M 39.86M 846.95K 7.72M 15.66M 27.91M 44.40M 89.93M 90.15M 130.46M
Cash Dividends to Common per Share		 - - - $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00

Quarterly Income Statements for Immunic

This table shows Immunic's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -24 -23 -22 -30 -21 -24 -25 -25 -27 -26 -19
Consolidated Net Income / (Loss)		 -24 -23 -22 -30 -21 -24 -25 -25 -27 -26 -19
Net Income / (Loss) Continuing Operations		 -24 -23 -22 -30 -21 -24 -25 -25 -27 -26 -19
Total Pre-Tax Income 		-24 -23 -22 -30 -21 -24 -25 -25 -27 -26 -19
Total Operating Income		 -25 -24 -23 -24 -23 -26 -26 -27 -27 -26 -23
Total Operating Expenses		 25 24 23 24 23 26 26 27 27 26 23
Selling, General & Admin Expense		 3.85 3.77 4.10 5.15 4.49 4.36 4.01 5.29 5.71 5.98 4.26
Research & Development Expense		 21 20 19 19 18 21 22 22 21 20 19
Total Other Income / (Expense), net		 1.02 0.80 1.81 -5.70 1.43 1.36 0.46 1.35 0.26 0.41 4.03
Interest & Investment Income		 0.97 0.77 0.54 1.19 1.00 0.78 0.43 0.18 0.24 0.42 0.20
Other Income / (Expense), net		 0.05 0.04 1.27 -6.89 0.44 0.58 0.03 1.17 0.02 -0.01 3.83
Basic Earnings per Share		 ($0.54) ($0.51) ($0.48) ($0.30) ($0.21) ($0.24) ($0.25) ($0.25) ($0.20) ($0.13) ($0.04)
Weighted Average Basic Shares Outstanding		 44.43M 44.57M 44.32M 97.30M 101.27M 101.27M 100.17M 101.34M 132.18M 193.90M 155.69M
Diluted Earnings per Share		 ($0.54) ($0.51) ($0.48) ($0.30) ($0.21) ($0.24) ($0.25) ($0.25) ($0.20) ($0.13) ($0.04)
Weighted Average Diluted Shares Outstanding		 44.43M 44.57M 44.32M 97.30M 101.27M 101.27M 100.17M 101.34M 132.18M 193.90M 155.69M
Weighted Average Basic & Diluted Shares Outstanding		 44.60M 45.15M 89.93M 90.08M 90.08M 90.08M 90.15M 95.82M 98.65M 120.28M 130.46M

Annual Cash Flow Statements for Immunic

This table details how cash moves in and out of Immunic's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -19 -23 -3.09 9.49 17 98 -41 20 -60 -11 -20
Net Cash From Operating Activities		 -50 -36 -40 -9.74 -29 -46 -83 -65 -71 -85 -86
Net Cash From Continuing Operating Activities		 -50 -36 -40 -9.74 -29 -46 -83 -65 -71 -85 -86
Net Income / (Loss) Continuing Operations		 -52 -41 -52 -12 -35 -44 -93 -120 -94 -101 -97
Consolidated Net Income / (Loss)		 -52 -41 -52 -12 -35 -44 -93 -120 -94 -101 -97
Depreciation Expense		 1.33 1.81 1.00 0.02 0.05 0.04 0.09 0.08 0.11 0.13 0.17
Non-Cash Adjustments To Reconcile Net Income		 4.03 4.76 5.74 0.00 7.70 0.22 19 46 7.63 15 9.36
Changes in Operating Assets and Liabilities, net		 -3.29 -1.38 4.95 1.79 -1.36 -2.37 -9.28 9.53 15 0.33 1.84
Net Cash From Investing Activities		 -1.28 -0.02 -0.68 -0.03 11 -0.15 -0.07 -9.74 9.46 -0.26 -0.16
Net Cash From Continuing Investing Activities		 -1.28 -0.02 -0.68 -0.03 11 -0.15 -0.07 -9.74 9.46 -0.26 -0.16
Purchase of Property, Plant & Equipment		 -2.34 -0.56 -0.69 -0.03 -0.06 -0.15 -0.07 -0.11 -0.33 -0.26 -0.16
Net Cash From Financing Activities		 32 12 38 19 35 144 43 96 1.03 75 66
Net Cash From Continuing Financing Activities		 32 12 38 19 35 144 43 96 1.03 75 66
Issuance of Debt		 - - - - - - - - 0.00 74 65
Issuance of Common Equity		 32 12 38 19 35 144 43 96 0.98 0.27 0.18
Effect of Exchange Rate Changes		 -0.01 -0.00 0.00 - - -0.08 -0.13 -0.99 0.26 -0.52 0.21

Quarterly Cash Flow Statements for Immunic

This table details how cash moves in and out of Immunic's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -15 -18 -13 51 -18 -21 -23 -21 41 -20 -20
Net Cash From Operating Activities		 -20 -17 -14 -24 -17 -21 -23 -22 -25 -20 -19
Net Cash From Continuing Operating Activities		 -20 -17 -14 -24 -17 -21 -23 -22 -25 -20 -19
Net Income / (Loss) Continuing Operations		 -24 -23 -22 -30 -21 -24 -25 -25 -27 -26 -19
Consolidated Net Income / (Loss)		 -24 -23 -22 -30 -21 -24 -25 -25 -27 -26 -19
Depreciation Expense		 0.02 0.03 0.02 0.03 0.03 0.04 0.04 0.04 0.04 0.04 0.04
Non-Cash Adjustments To Reconcile Net Income		 1.95 1.73 1.45 9.75 1.56 1.98 2.11 2.10 1.85 3.61 1.81
Changes in Operating Assets and Liabilities, net		 2.05 3.69 6.07 -4.17 2.75 1.55 0.07 1.56 0.21 1.74 -1.67
Net Cash From Investing Activities		 4.34 -0.04 -0.17 -0.03 -0.18 -0.05 -0.00 -0.05 -0.04 -0.07 -0.01
Net Cash From Continuing Investing Activities		 4.34 -0.04 -0.17 -0.03 -0.18 -0.05 -0.00 -0.05 -0.04 -0.07 -0.01
Purchase of Property, Plant & Equipment		 -0.02 -0.04 -0.17 -0.03 -0.18 -0.05 -0.00 -0.05 -0.04 -0.07 -0.01
Net Cash From Financing Activities		 0.10 0.28 0.60 74 - - 0.08 0.00 66 - 0.06
Net Cash From Continuing Financing Activities		 0.10 0.28 0.60 74 - - 0.08 0.00 65 - 0.18
Issuance of Common Equity		 0.10 0.28 0.60 0.19 - - 0.08 0.00 - - 0.18
Effect of Exchange Rate Changes		 0.08 -0.53 0.57 0.17 -0.40 0.22 -0.51 0.46 0.13 0.03 -0.42

Annual Balance Sheets for Immunic

This table presents Immunic's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 89 64 60 13 66 168 139 128 54 41 24
Total Current Assets		 85 61 58 13 32 134 105 126 53 39 23
Cash & Equivalents		 83 60 57 13 29 127 87 107 47 36 15
Prepaid Expenses		 1.14 1.47 1.22 0.26 2.86 6.29 18 9.49 5.86 3.66 7.39
Plant, Property, & Equipment, net		 3.81 2.51 2.16 0.04 0.08 0.20 0.15 0.29 0.47 0.55 0.61
Total Noncurrent Assets		 0.18 0.06 0.11 0.00 34 34 34 1.60 1.30 0.99 0.58
Other Noncurrent Operating Assets		 0.18 0.06 0.11 0.00 0.68 0.94 0.99 1.60 1.30 0.99 0.58
Total Liabilities & Shareholders' Equity		 89 64 60 13 66 168 139 128 54 41 24
Total Liabilities		 6.76 5.58 10 1.92 7.59 9.08 12 14 25 22 31
Total Current Liabilities		 6.66 5.48 10 1.92 7.07 8.40 11 13 25 22 31
Accounts Payable		 1.22 0.78 1.05 1.40 2.42 3.70 3.75 4.28 5.10 7.85 10
Accrued Expenses		 5.27 4.66 9.14 0.42 3.30 4.32 7.07 7.99 19 13 19
Other Current Liabilities		 0.16 0.04 0.09 0.10 1.35 0.38 0.59 0.81 0.97 1.42 1.84
Total Noncurrent Liabilities		 0.10 0.10 0.06 0.00 0.52 0.68 0.58 0.99 0.64 0.26 0.11
Other Noncurrent Operating Liabilities		 0.10 0.10 0.06 0.00 0.52 0.68 0.58 0.99 0.64 0.26 0.11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 82 58 50 -26 58 159 127 114 29 18 -6.67
Total Preferred & Common Equity		 82 58 50 -26 58 159 127 114 29 18 -6.67
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 82 58 50 -26 58 159 127 114 29 18 -6.67
Common Stock		 285 302 346 0.06 120 267 324 428 436 526 599
Retained Earnings		 -203 -244 -296 -25 -60 -104 -197 -317 -411 -511 -609
Accumulated Other Comprehensive Income / (Loss)		 0.08 0.08 0.08 -0.82 -1.37 -4.11 -0.25 3.04 3.76 4.21 2.65

Quarterly Balance Sheets for Immunic

This table presents Immunic's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 89 67 104 86 65 21 61 41
Total Current Assets		 87 65 103 85 63 19 60 39
Cash & Equivalents		 77 60 97 80 59 14 55 35
Prepaid Expenses		 9.26 5.55 5.30 5.28 4.20 4.67 4.53 4.14
Plant, Property, & Equipment, net		 0.29 0.29 0.44 0.59 0.62 0.57 0.61 0.64
Total Noncurrent Assets		 1.90 1.46 1.10 0.93 0.88 0.97 0.98 0.79
Other Noncurrent Operating Assets		 1.90 1.46 1.10 0.93 0.88 0.97 0.98 0.79
Total Liabilities & Shareholders' Equity		 89 67 104 86 65 21 61 41
Total Liabilities		 19 19 21 23 24 26 28 30
Total Current Liabilities		 18 18 20 23 23 26 27 30
Accounts Payable		 4.70 3.20 6.77 7.89 6.04 6.01 7.89 7.92
Accrued Expenses		 13 14 12 14 16 18 18 19
Other Current Liabilities		 0.93 0.92 0.96 1.01 1.07 1.29 1.31 2.71
Total Noncurrent Liabilities		 1.21 0.79 0.43 0.24 0.19 0.21 0.21 0.13
Other Noncurrent Operating Liabilities		 1.21 0.79 0.43 0.24 0.19 0.21 0.21 0.13
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 69 48 84 64 41 -5.29 34 10
Total Preferred & Common Equity		 69 48 84 64 41 -5.29 34 10
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 69 48 84 64 41 -5.29 34 10
Common Stock		 432 434 520 522 524 528 595 597
Retained Earnings		 -367 -389 -440 -462 -486 -537 -564 -589
Accumulated Other Comprehensive Income / (Loss)		 3.98 3.91 4.29 3.78 3.89 3.92 2.53 2.58

Annual Metrics And Ratios for Immunic

This table displays calculated financial ratios and metrics derived from Immunic's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 30,425,686.00 32,050,850.00 42,207,376.00 42,369,694.00 10,117,036.00 20,718,340.00 26,249,439.00 39,261,547.00 45,145,383.00 - 120,284,724.00
DEI Adjusted Shares Outstanding		 760,642.00 801,271.00 1,055,184.00 1,059,242.00 10,117,036.00 20,718,340.00 26,249,439.00 39,261,547.00 45,145,383.00 - 120,284,724.00
DEI Earnings Per Adjusted Shares Outstanding		 -68.39 -51.13 -49.35 -10.90 -3.45 -2.12 -3.54 -3.07 -2.07 - -0.81
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -8.91% 22.28% -31.14% 77.72% -203.57% -25.85% -111.02% -30.61% 20.43% -7.44% 5.51%
EBIT Growth		 -9.22% 20.79% -27.82% 78.11% -203.61% -25.78% -111.03% -30.57% 20.39% -7.46% 5.47%
NOPAT Growth		 -3.53% 20.83% -27.60% 77.22% -208.68% -32.24% -87.18% -30.35% 16.96% 1.18% -5.28%
Net Income Growth		 -9.14% 21.25% -27.12% 77.84% -202.66% -26.00% -111.16% -29.55% 22.25% -7.37% 3.32%
EPS Growth		 41.53% 36.72% 0.00% 77.84% 66.84% 37.83% -39.86% 3.82% 44.18% 52.61% 38.00%
Operating Cash Flow Growth		 -22.36% 28.38% -12.92% 75.89% -193.13% -61.58% -80.45% 21.73% -8.73% -19.68% -1.23%
Free Cash Flow Firm Growth		 -40.35% 29.57% -8.91% 56.78% -314.68% 35.23% -99.58% 44.31% -33.67% -27.09% 2.60%
Invested Capital Growth		 74.09% 4.86% -343.82% 76.36% 1,888.65% 8.07% 28.47% -106.68% -559.59% 2.84% -28.52%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 7.69% -5.06% -6.52% 65.68% -76.65% -8.63% -12.01% -42.16% 26.64% -3.47% 5.87%
EBIT Q/Q Growth		 7.26% -4.89% -5.99% 65.87% -76.52% -8.53% -12.09% -42.08% 26.61% -3.48% 5.85%
NOPAT Q/Q Growth		 7.34% -4.92% -5.95% 64.45% -69.28% -13.97% -8.95% -42.45% 25.49% -2.35% 2.18%
Net Income Q/Q Growth		 7.30% -4.80% -5.80% 65.49% -75.29% -8.55% -12.09% -41.46% 27.16% -3.72% 5.70%
EPS Q/Q Growth		 -110.00% -5.65% -11.97% 65.49% -127.14% -29.49% -19.09% -31.71% 35.28% 18.70% 25.30%
Operating Cash Flow Q/Q Growth		 2.16% 0.53% -2.07% 39.94% -10.96% -20.03% -13.22% 11.63% 1.50% -11.78% 4.11%
Free Cash Flow Firm Q/Q Growth		 -0.99% 1.25% -2.35% 44.10% -15.56% -23.29% -13.80% 31.87% -18.53% -14.30% -0.37%
Invested Capital Q/Q Growth		 24.29% -346.53% -58.98% 54.29% -3.57% 5.53% 14.94% -107.46% -57.27% 3.43% 10.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.89% 99.31% 98.77% 100.01% 99.69% 99.87% 99.93% 99.14% 96.82% 96.74% 98.94%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -57.84% -58.21% -96.01% -94.98% -214.17% -40.54% -65.02% -100.01% -131.28% -424.44% -1,653.15%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -195.00% -121.40% -204.19% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -57.84% -58.21% -96.01% -94.98% -214.17% -40.54% -65.02% -100.01% -131.28% -424.44% -1,653.15%
Return on Equity Simple (ROE_SIMPLE)		 -63.19% -70.10% -104.06% 44.84% -59.85% -27.72% -73.12% -105.91% -323.57% -545.37% 0.00%
Net Operating Profit after Tax (NOPAT)		 -36 -29 -37 -8.40 -26 -34 -64 -84 -69 -69 -72
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -16.55% -16.79% -26.04% -19.18% -343.33% -12.42% -26.86% -36.18% -29.63% -77.41% -97.41%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -240.08% -372.44% 1,082.87%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -52 -41 -53 -12 -35 -44 -93 -121 -97 -104 -98
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -51 -39 -52 -12 -35 -44 -93 -121 -97 -104 -98
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.26 2.39 5.02 0.00 1.68 2.00 1.98 0.48 2.34 4.89 0.00
Price to Tangible Book Value (P/TBV)		 4.26 2.39 5.02 0.00 3.86 2.52 2.67 0.48 2.34 4.89 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 2.37 6.04 4.08 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.02 -1.08 -1.35 -0.16 -0.72 -0.75 -0.84 -1.14 -1.74 -4.35
Leverage Ratio		 1.10 1.09 1.15 3.03 2.43 1.08 1.07 1.11 1.28 2.01 5.52
Compound Leverage Factor		 1.09 1.08 1.13 3.04 2.42 1.08 1.07 1.10 1.24 1.94 5.46
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 27.07 8.58 5.78 -1.97 5.19 20.10 9.20 -3.21 -14.25 -23.00 -48.03
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.79 11.22 5.65 6.94 4.56 15.93 9.21 9.62 2.12 1.77 0.75
Quick Ratio		 12.53 10.95 5.53 6.81 4.15 15.18 7.62 8.90 1.89 1.61 0.51
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -41 -29 -32 -14 -57 -37 -73 -41 -54 -69 -67
Operating Cash Flow to CapEx		 -2,134.70% -6,457.40% -5,958.26% -30,431.25% 0.00% -31,591.78% -124,228.36% -58,164.29% -21,205.99% -32,108.33% -53,295.65%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.62 -1.55 -6.86 -1.62 29 31 40 -2.69 -18 -17 -22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 4.64 0.08 -5.31 5.24 31 2.34 8.92 -43 -15 0.50 -4.92
Enterprise Value (EV)		 267 79 194 -5.18 69 189 164 -61 21 54 49
Market Capitalization		 351 139 251 7.89 98 317 251 55 68 90 64
Book Value per Share		 $2.71 $1.82 $1.19 ($0.61) $5.77 $7.66 $4.84 $2.90 $0.64 $0.20 ($0.06)
Tangible Book Value per Share		 $2.71 $1.82 $1.19 ($0.61) $2.51 $6.07 $3.59 $2.90 $0.64 $0.20 ($0.06)
Total Capital		 82 58 50 -26 58 159 127 114 29 18 -6.67
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -84 -60 -57 -13 -29 -127 -87 -116 -47 -36 -15
Capital Expenditures (CapEx)		 2.34 0.55 0.68 0.03 -2.46 0.15 0.07 0.11 0.33 0.26 0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.52 -4.01 -9.06 -1.66 -4.21 -2.10 6.72 -3.59 -19 -19 -23
Debt-free Net Working Capital (DFNWC)		 78 56 48 11 25 125 94 113 28 17 -7.75
Net Working Capital (NWC)		 78 56 48 11 25 125 94 113 28 17 -7.75
Net Nonoperating Expense (NNE)		 16 12 15 3.14 9.01 9.74 29 37 24 32 25
Net Nonoperating Obligations (NNO)		 -84 -60 -57 24 -29 -127 -87 -116 -47 -36 -15
Total Depreciation and Amortization (D&A)		 1.33 1.81 1.00 0.02 0.05 0.04 0.09 0.08 0.11 0.13 0.17
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($82.80) ($52.40) ($52.40) ($39.20) ($4.52) ($2.81) ($3.93) ($3.78) ($2.11) ($1.00) ($0.62)
Adjusted Weighted Average Basic Shares Outstanding		 761.86K 803.62K 1.06M 1.06M 10.74M 21.17M 23.65M 31.82M 44.32M 100.17M 155.69M
Adjusted Diluted Earnings per Share		 ($82.80) ($52.40) ($52.40) ($39.20) ($4.52) ($2.81) ($3.93) ($3.78) ($2.11) ($1.00) ($0.62)
Adjusted Weighted Average Diluted Shares Outstanding		 761.86K 803.62K 1.06M 1.06M 10.74M 21.17M 23.65M 31.82M 44.32M 100.17M 155.69M
Adjusted Basic & Diluted Earnings per Share		 ($82.80) ($52.40) ($52.40) ($39.20) ($4.52) ($2.81) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 628.82K 784.69K 996.48K 1.06M 7.72M 15.66M 27.91M 44.40M 89.93M 90.15M 130.46M
Normalized Net Operating Profit after Tax (NOPAT)		 -36 -29 -37 -8.40 -26 -34 -64 -61 -69 -69 -72
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Immunic

This table displays calculated financial ratios and metrics derived from Immunic's official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 44,403,838.00 44,595,383.00 45,145,383.00 45,145,383.00 90,079,016.00 90,079,016.00 - 90,150,869.00 95,817,536.00 98,650,590.00 120,284,724.00
DEI Adjusted Shares Outstanding		 44,403,838.00 44,595,383.00 45,145,383.00 45,145,383.00 90,079,016.00 90,079,016.00 - 90,150,869.00 95,817,536.00 98,650,590.00 120,284,724.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.54 -0.51 -0.48 -0.66 -0.24 -0.27 - -0.28 -0.28 -0.26 -0.16
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -13.45% -9.63% 61.35% -18.07% 10.41% -6.81% -15.75% 16.69% -20.90% -3.41% 23.91%
EBIT Growth		 -13.45% -9.70% 61.32% -18.02% 10.37% -6.84% -15.79% 16.62% -20.93% -3.40% 23.85%
NOPAT Growth		 -21.40% -17.17% 59.21% 12.37% 8.82% -9.15% -9.62% -12.33% -18.71% -1.04% 8.99%
Net Income Growth		 -9.58% -7.28% 61.80% -17.06% 10.91% -7.02% -16.70% 13.90% -25.44% -4.97% 23.34%
EPS Growth		 25.00% 26.09% 70.55% 48.28% 61.11% 52.94% 47.92% 16.67% 4.76% 45.83% 84.00%
Operating Cash Flow Growth		 -26.73% -27.33% 7.13% -22.84% 14.70% -20.12% -63.71% 9.15% -44.43% 3.15% 16.03%
Free Cash Flow Firm Growth		 246.71% 304.13% -146.70% -130.53% -125.95% -137.11% -1,304.10% -45.61% -74.21% 0.21% 38.13%
Invested Capital Growth		 -120.14% -131.31% -559.59% -133.05% -101.31% -58.23% 2.84% -42.63% -32.71% -37.98% -28.52%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 4.21% 5.79% 6.00% -39.18% 27.32% -12.33% -1.86% -0.17% -5.49% 3.92% 25.05%
EBIT Q/Q Growth		 4.24% 5.74% 6.04% -39.15% 27.28% -12.36% -1.83% -0.20% -5.48% 3.93% 25.01%
NOPAT Q/Q Growth		 8.18% 5.80% 0.80% -2.14% 4.47% -12.76% 0.37% -4.66% -0.96% 4.02% 10.26%
Net Income Q/Q Growth		 5.04% 5.13% 5.26% -37.14% 27.73% -13.98% -3.31% -1.18% -5.29% 4.63% 24.55%
EPS Q/Q Growth		 6.90% 5.56% 5.88% 37.50% 30.00% -14.29% -4.17% 0.00% 20.00% 35.00% 69.23%
Operating Cash Flow Q/Q Growth		 -2.37% 13.34% 18.98% -70.88% 28.91% -22.04% -10.38% 5.17% -13.01% 18.16% 4.27%
Free Cash Flow Firm Q/Q Growth		 4.11% 1.84% -104.26% -575.55% 11.49% -45.62% -61.26% 29.94% -5.89% 16.59% 0.02%
Invested Capital Q/Q Growth		 -35.90% -40.85% -57.27% 22.58% -17.39% -10.71% 3.43% -13.64% -9.23% -15.11% 10.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.12% 96.75% 97.55% 96.14% 95.54% 96.91% 98.32% 99.29% 99.11% 98.39% 98.99%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -128.82% -163.49% -131.28% -112.05% -143.47% -216.24% -424.44% -246.26% -208.93% -398.50% -1,653.15%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -128.82% -163.49% -131.28% -112.05% -143.47% -216.24% -424.44% -246.26% -208.93% -398.50% -1,653.15%
Return on Equity Simple (ROE_SIMPLE)		 -183.26% -265.49% 0.00% -117.17% 0.00% 0.00% 0.00% 1,823.26% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -16 -16 -17 -16 -18 -18 -19 -19 -18 -16
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -7.84% -9.47% -6.39% -13.24% -6.89% -10.71% -17.57% -12.00% -11.65% -15.68% -11.62%
Return On Investment Capital (ROIC_SIMPLE)		 - - -56.57% -20.00% -25.12% -43.69% -97.36% 355.16% -55.91% -173.30% 244.70%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -25 -24 -22 -31 -22 -25 -26 -26 -27 -26 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -24 -22 -31 -22 -25 -26 -26 -27 -26 -19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.61 1.35 2.34 0.71 1.57 3.61 4.89 0.00 1.97 8.28 0.00
Price to Tangible Book Value (P/TBV)		 1.61 1.35 2.34 0.71 1.57 3.61 4.89 0.00 1.97 8.28 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.84 -0.84 -1.14 -1.11 -1.18 -1.33 -1.74 -1.43 -1.38 -1.82 -4.35
Leverage Ratio		 1.15 1.20 1.28 1.22 1.32 1.47 2.01 1.59 1.52 2.04 5.52
Compound Leverage Factor		 1.11 1.16 1.25 1.17 1.26 1.42 1.98 1.58 1.50 2.01 5.47
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.35 -6.33 -9.72 -4.21 -4.85 -7.26 -16.67 -38.87 -12.21 -20.38 -37.23
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.74 3.67 2.12 5.09 3.75 2.71 1.77 0.74 2.19 1.31 0.75
Quick Ratio		 4.24 3.36 1.89 4.83 3.51 2.53 1.61 0.56 2.03 1.17 0.51
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 30 31 -1.31 -8.87 -7.85 -11 -18 -13 -14 -11 -11
Operating Cash Flow to CapEx		 -95,123.81% -39,345.45% -8,501.21% -77,319.35% -9,466.11% -41,590.00% -765,433.33% -46,331.91% -68,358.33% -30,059.70% -175,281.82%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.01 -11 -18 -14 -16 -18 -17 -20 -21 -25 -22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -48 -47 -15 -7.84 -8.12 -6.57 0.50 -5.86 -5.27 -6.78 -4.92
Enterprise Value (EV)		 34 5.87 21 -38 20 90 54 84 12 52 49
Market Capitalization		 111 66 68 60 100 149 90 98 67 87 64
Book Value per Share		 $1.56 $1.09 $0.64 $0.86 $0.71 $0.46 $0.20 ($0.06) $0.35 $0.11 ($0.06)
Tangible Book Value per Share		 $1.56 $1.09 $0.64 $0.86 $0.71 $0.46 $0.20 ($0.06) $0.35 $0.11 ($0.06)
Total Capital		 69 48 29 84 64 41 18 -5.29 34 10 -6.67
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -77 -60 -47 -97 -80 -59 -36 -14 -55 -35 -15
Capital Expenditures (CapEx)		 0.02 0.04 0.17 0.03 0.18 0.05 0.00 0.05 0.04 0.07 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.98 -12 -19 -15 -17 -19 -19 -21 -23 -26 -23
Debt-free Net Working Capital (DFNWC)		 68 47 28 82 62 40 17 -6.62 33 9.19 -7.75
Net Working Capital (NWC)		 68 47 28 82 62 40 17 -6.62 33 9.19 -7.75
Net Nonoperating Expense (NNE)		 6.48 6.27 5.21 13 5.41 6.36 7.23 6.70 7.86 7.38 2.97
Net Nonoperating Obligations (NNO)		 -77 -60 -47 -97 -80 -59 -36 -14 -55 -35 -15
Total Depreciation and Amortization (D&A)		 0.02 0.03 0.02 0.03 0.03 0.04 0.04 0.04 0.04 0.04 0.04
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.54) ($0.51) ($0.48) ($0.30) ($0.21) ($0.24) ($0.25) ($0.25) ($0.20) ($0.13) ($0.04)
Adjusted Weighted Average Basic Shares Outstanding		 44.43M 44.57M 44.32M 97.30M 101.27M 101.27M 100.17M 101.34M 132.18M 193.90M 155.69M
Adjusted Diluted Earnings per Share		 ($0.54) ($0.51) ($0.48) ($0.30) ($0.21) ($0.24) ($0.25) ($0.25) ($0.20) ($0.13) ($0.04)
Adjusted Weighted Average Diluted Shares Outstanding		 44.43M 44.57M 44.32M 97.30M 101.27M 101.27M 100.17M 101.34M 132.18M 193.90M 155.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 44.60M 45.15M 89.93M 90.08M 90.08M 90.08M 90.15M 95.82M 98.65M 120.28M 130.46M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -16 -16 -17 -16 -18 -18 -19 -19 -18 -16
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways for Immunic (IMUX) based on the latest quarterly data provided. The bullets focus on trends over the last four years of statements, with a view toward what may matter for retail investors.

  • Significant financing activity in early 2025: Q1 2025 net financing inflow around $74.46 million and Q2 2025 around $65.52 million helped boost liquidity in the first half of 2025.
  • Earnings per share show sequential improvement through 2025: Diluted EPS improved from about -0.25 in Q1 2025 to -0.04 in Q4 2025, indicating losses per share narrowed over the year.
  • Non-cash adjustments cushioned cash flow in several quarters: non-cash items ranged roughly from $1.8 million to $3.6 million in key periods (e.g., Q3 2025 $3.614 million; Q4 2025 $1.805 million; Q4 2024 $2.106 million).
  • No revenue in the latest quarters: Total revenue is effectively zero in Q1–Q4 2025 (and in prior years from the data provided), signaling a pre-revenue development stage rather than a commercial product contribution.
  • Investing cash flows are small and mostly limited to modest PPE outlays: net investing cash flow figures show only minor cash outflows in the periods shown.
  • Balance sheet suggests a thin equity cushion with a large accumulated deficit: retained earnings are deeply negative, and total equity remains small relative to liabilities in several periods.
  • Persistent net losses: Q4 2025 net income was -$19.3 million (Q3 2025 around -$25.6M; Q2 2025 around -$26.8M; Q1 2025 around -$25.5M), underscoring ongoing profitability challenges.
  • Operating cash burn remains, with variable intensity: net cash from continuing operating activities was negative in all of the latest quarters (e.g., around -$19.1 million in Q4 2025; -$24.7 million in Q2 2025), indicating ongoing cash burn from core operations.
  • Reliance on external financing to fund operations: large financing inflows occurred in early 2025, but there is no sustained revenue offset, raising liquidity-coverage questions if financing markets tighten.
05/05/26 06:32 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Immunic's Financials

When does Immunic's fiscal year end?

According to the most recent income statement we have on file, Immunic's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Immunic's net income changed over the last 10 years?

Immunic's net income appears to be on an upward trend, with a most recent value of -$97.17 million in 2025, rising from -$52.02 million in 2015. The previous period was -$100.51 million in 2024. See Immunic's forecast for analyst expectations on what’s next for the company.

What is Immunic's operating income?
Immunic's total operating income in 2025 was -$103.23 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $103.23 million
How has Immunic's revenue changed over the last 10 years?

Over the last 10 years, Immunic's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

How much debt does Immunic have?

Immunic's total liabilities were at $30.73 million at the end of 2025, a 36.9% increase from 2024, and a 354.8% increase since 2015.

How much cash does Immunic have?

In the past 10 years, Immunic's cash and equivalents has ranged from $13.07 million in 2018 to $127.45 million in 2020, and is currently $15.48 million as of their latest financial filing in 2025.

How has Immunic's book value per share changed over the last 10 years?

Over the last 10 years, Immunic's book value per share changed from 2.71 in 2015 to -0.06 in 2025, a change of -102.1%.


Related Companies

Financial statements for NASDAQ:IMUX last updated on 4/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel